Literature DB >> 22544173

Misoprostol prior to hysteroscopy in premenopausal and post-menopausal women. A systematic review and meta-analysis.

N P Polyzos1, A Zavos, A Valachis, C Dragamestianos, C Blockeel, D Stoop, E G Papanikolaou, H Tournaye, P Devroey, I E Messinis.   

Abstract

BACKGROUND: Although several randomized controlled trials (RCTs) have examined the effect of misoprostol prior to hysteroscopy for cervical dilatation, no solid conclusion has been reached. We therefore set out to perform a meta-analysis of RCTs.
METHODS: We searched MEDLINE, the ISI Web of Science and the Cochrane Library to identify RCTs comparing misoprostol versus placebo or control prior to hysteroscopy. No restrictions on language or time were applied. Relative risks (RRs) and 95% confidence intervals (CIs) were calculated for all dichotomous outcomes, whereas mean differences (MDs) and 95% CIs were calculated for continuous outcomes using the Mantel-Haenszel or DerSimonian-Laird model according to the heterogeneity.
RESULTS: Of the initial 141 potentially relevant articles that were retrieved, 21 RCTs involving 1786 patients were included in the meta-analysis. Subgroup analyses were performed according to menopausal status and according to whether diagnostic or operative hysteroscopy was performed. Premenopausal women treated with misoprostol had a significantly lower risk for further cervical dilatation in the diagnostic setting [RR (95% CI): 0.56 (0.34-0.92)] and a significantly lower risk for cervical laceration in the operative setting [RR (95% CI): 0.22 (0.09-0.54)], compared with placebo. In contrast, post-menopausal patients did not experience any clear benefit from misoprostol compared with placebo regarding the need for further cervical dilatation [RR (95% CI): 0.99 (0.76-1.30)] and the cervical laceration rate [RR (95% CI): 1.15 (0.40-3.29)]. In addition, the mean cervical width prior to hysteroscopy was significantly higher in premenopausal women treated with misoprostol compared with placebo [MD (95% CI): 2.47 mm (1.81-3.13)] but did not differ among post-menopausal patients [MD (95% CI): 0.39 mm (-0.42 to 1.21)].
CONCLUSIONS: Misoprostol prior to hysteroscopy appears to facilitate an easier and uncomplicated procedure only in premenopausal women.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544173     DOI: 10.1093/humupd/dms014

Source DB:  PubMed          Journal:  Hum Reprod Update        ISSN: 1355-4786            Impact factor:   15.610


  6 in total

1.  Effectiveness of Misoprostol in Office Hysteroscopy in Premenopausal Nulliparous Women: A Prospective Randomized Double-Blind Placebo-Controlled Trial.

Authors:  Vinod G Nair; Kallol Kumar Roy; Rakhi Rai; Anamika Das; Juhi Bharti; Rinchen Zangmo
Journal:  J Hum Reprod Sci       Date:  2020-07-09

2.  Cervical Priming by Misoprostol before Diagnostic Dilatation and Curettage: A Randomized Clinical Trial.

Authors:  Shima Mohammadian; Anahita Tavana; Shahrzad Tavana; Aida Mohammadian; Masoumeh Fallahian
Journal:  J Reprod Infertil       Date:  2015 Jul-Sep

3.  Efficacy of hyoscine in pain management during hysteroscopy: a systematic review and meta-analysis

Authors:  Greg J. Marchand; Wesam Kurdi; Katelyn Sainz; Hiba Maarouf; Kelly Ware; Ahmed Taher Masoud; Alexa King; Stacy Ruther; Giovanna Brazil; Kaitlynne Cieminski; Nicolas Calteux; Hollie Ulibarri; Julia Parise; Amanda Arroyo; Diana Chen; Maria Pierson; Rasa Rafie; Mohammad Abrar Shareef
Journal:  J Turk Ger Gynecol Assoc       Date:  2021-12-06

4.  Role of vaginal estradiol pretreatment combined with vaginal misoprostol for cervical ripening before operative hysteroscopy in postmenopausal women.

Authors:  Luisa Casadei; Eleonora Piccolo; Claudia Manicuti; Silvia Cardinale; Matteo Collamarini; Emilio Piccione
Journal:  Obstet Gynecol Sci       Date:  2016-05-13

5.  The use of misoprostol for cervical priming prior to hysteroscopy: a systematic review and analysis.

Authors:  Ying Hua; Wenwen Zhang; Xiaoli Hu; Ansu Yang; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-09-06       Impact factor: 4.162

6.  Anaphylactic shock to vaginal misoprostol: a rare adverse reaction to a frequently used drug.

Authors:  Hyun Joo Shin; Sa Ra Lee; A-Mi Roh; Young-Mee Lim; Kyung Ah Jeong; Hye-Sung Moon; Hye Won Chung
Journal:  Obstet Gynecol Sci       Date:  2018-08-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.